LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
![Foto de LUIS GONZAGA](/img/nophoto.png)
![Foto de McGill University](/img/noimage_org.png)
McGill University
Montreal, CanadáPublicaciones en colaboración con investigadores/as de McGill University (9)
2024
-
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Annals of Oncology
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
2023
-
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
New England Journal of Medicine, Vol. 389, Núm. 8, pp. 710-721
2018
-
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
Clinical Lung Cancer, Vol. 19, Núm. 4, pp. e465-e479
2017
-
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
Annals of Oncology, Vol. 28, Núm. 2, pp. 270-277
2016
-
140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S117-S118
-
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
The Lancet Oncology, Vol. 17, Núm. 5, pp. 577-589
2011
-
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
British Journal of Cancer, Vol. 104, Núm. 1, pp. 68-74
2009
-
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin
Journal of Thoracic Oncology, Vol. 4, Núm. 11, pp. 1397-1403